| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1032061107 |
| P356 | DOI | 10.1186/1471-2407-12-462 |
| P932 | PMC publication ID | 3523201 |
| P698 | PubMed publication ID | 23046546 |
| P5875 | ResearchGate publication ID | 232224606 |
| P2093 | author name string | Akinobu Kurita | |
| Akimitsu Takagi | |||
| Hiroaki Konishi | |||
| Norimasa Kaneda | |||
| Takeshi Matsuzaki | |||
| P2860 | cites work | Long-term survival and patterns of care in women with ovarian tumors of low malignant potential | Q74342930 |
| Comparative in vivo studies with paclitaxel and liposome-encapsulated paclitaxel | Q74430099 | ||
| Involvement of SDF-1alpha/CXCR4 axis in the enhanced peritoneal metastasis of epithelial ovarian carcinoma | Q81348863 | ||
| Predictive value of symptoms for early detection of ovarian cancer | Q24644590 | ||
| Vascular cell adhesion molecule-1 is a regulator of ovarian cancer peritoneal metastasis | Q30447841 | ||
| Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer | Q32073515 | ||
| Screening postmenopausal women for ovarian cancer: a systematic review | Q33205889 | ||
| Mutation analysis of BRAF, MEK1 and MEK2 in 15 ovarian cancer cell lines: implications for therapy | Q33308740 | ||
| Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results | Q33332312 | ||
| Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the G | Q33335882 | ||
| Clinical characteristics of clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy | Q33947083 | ||
| Mutations and response to epidermal growth factor receptor inhibitors | Q37396680 | ||
| Antitumor activity of IHL-305, a novel pegylated liposome containing irinotecan, in human xenograft models | Q39470611 | ||
| Improved therapeutic activity of folate-targeted liposomal doxorubicin in folate receptor-expressing tumor models | Q39795451 | ||
| Her2-targeted pegylated liposomal doxorubicin: retention of target-specific binding and cytotoxicity after in vivo passage | Q39866499 | ||
| Heparin-binding epidermal growth factor-like growth factor promotes transcoelomic metastasis in ovarian cancer through epithelial-mesenchymal transition | Q39929756 | ||
| Biopharmaceutical Considerations in Subcutaneous and Intramuscular Drug Administration | Q39971489 | ||
| Three-dimensional cellular spheroid formation provides human prostate tumor cells with tissue-like features | Q40160493 | ||
| Overexpression of HMGA1 promotes anoikis resistance and constitutive Akt activation in pancreatic adenocarcinoma cells | Q40162429 | ||
| Health-related quality of life during and after intraperitoneal versus intravenous chemotherapy for optimally debulked ovarian cancer: a Gynecologic Oncology Group Study | Q40247128 | ||
| Transduction of soluble Flt-1 gene to peritoneal mesothelial cells can effectively suppress peritoneal metastasis of gastric cancer | Q40554362 | ||
| Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer | Q40673230 | ||
| Evaluation of pharmacokinetics of 111In-labeled VNB-PEGylated liposomes after intraperitoneal and intravenous administration in a tumor/ascites mouse model | Q43289077 | ||
| Uptake of liposomes by cultured mouse bone marrow macrophages: influence of liposome composition and size | Q47434536 | ||
| Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. | Q50512108 | ||
| Intraperitoneal cisplatin and paclitaxel in ovarian cancer. | Q53263238 | ||
| Phase II study of CPT-11, a new camptothecin derivative, in metastatic colorectal cancer. CPT-11 Gastrointestinal Cancer Study Group. | Q54241012 | ||
| Comparison of 3D and 2D tumor models reveals enhanced HER2 activation in 3D associated with an increased response to trastuzumab. | Q54791338 | ||
| CPT-11: a new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer | Q67492629 | ||
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | ovarian cancer | Q172341 |
| P304 | page(s) | 462 | |
| P577 | publication date | 2012-10-10 | |
| P1433 | published in | BMC Cancer | Q326300 |
| P1476 | title | PEGylated liposome IHL-305 markedly improved the survival of ovarian cancer peritoneal metastasis in mouse | |
| P478 | volume | 12 |
| Q36071814 | Evaluation of the efficiency of tumor and tissue delivery of carrier-mediated agents (CMA) and small molecule (SM) agents in mice using a novel pharmacokinetic (PK) metric: relative distribution index over time (RDI-OT). |
| Q55094118 | Irinotecan Liposome Injection. |
| Q33590704 | MicroRNA-7 inhibits tumor metastasis and reverses epithelial-mesenchymal transition through AKT/ERK1/2 inactivation by targeting EGFR in epithelial ovarian cancer |
| Q51210425 | Population pharmacokinetics of PEGylated liposomal CPT-11 (IHL-305) in patients with advanced solid tumors. |
| Q39682085 | The relevance of using 3D cell cultures, in addition to 2D monolayer cultures, when evaluating breast cancer drug sensitivity and resistance |
Search more.